|1.||Hamelink, Elizabeth: 3 articles (06/2005 - 03/2003)|
|2.||Samuelsson, Bertil: 3 articles (06/2005 - 03/2003)|
|3.||Rosenquist, Asa: 3 articles (06/2005 - 03/2003)|
|4.||Vrang, Lotta: 3 articles (06/2005 - 03/2003)|
|5.||Hallberg, Anders: 3 articles (06/2005 - 03/2003)|
|6.||Kvarnström, Ingemar: 3 articles (06/2005 - 03/2003)|
|7.||Blackman, Michael J: 2 articles (06/2005 - 06/2004)|
|8.||Johansson, Per-Ola: 2 articles (06/2005 - 06/2004)|
|9.||Gröschel, Klaus: 1 article (03/2015)|
|10.||Vahl, Christian-Friedrich: 1 article (03/2015)|
06/30/2005 - "New and potent inhibitors of the malarial aspartic proteases plasmepsin (Plm) I and II, from the deadliest malaria parasite Plasmodium falciparum, have been synthesized utilizing Suzuki coupling reactions on previously synthesized bromobenzyloxy-substituted statine-like inhibitors. "
06/17/2004 - "Picomolar to low nanomolar inhibitors of the two aspartic proteases plasmepsin (Plm) I and II, from the malaria parasite Plasmodium falciparum, have been identified from sets of libraries containing novel statine-like templates modified at the amino and carboxy terminus. "
06/17/2004 - "Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs."
03/20/2003 - "With the aim to develop inhibitors of the plasmepsin I and II aspartic proteases of the malaria parasite Plasmodium falciparum, we have synthesized sets of libraries from novel reversed-statine isosteres, using a combination of solution phase and solid phase chemistry. "
|2.||Muscular Diseases (Myopathy)
02/01/2003 - "If they establish the diagnosis of fibrate/statine myopathy, lipid lowering drugs should be immediately withdrawn. "
02/01/2003 - "In case of clinical signs of a fibrate/statine myopathy such as proximal myalgias, stiffness,weakness, and dark urine, appropriate investigations should be initiated. "
02/01/2003 - "[Fibrate and statine myopathy]."
04/01/1991 - "Combinations of drugs (for example, a fibrate and a statine or cyclosporin and colchicine) can induce severe myopathies. "
02/01/2003 - "The risk of fibrate/statine myopathy, the most common side effect of fibrate/statine therapy, increases with dosage, combination of a fibrate with a statine,hypothyroidism, renal insufficiency, and intake of cytochrome P450 inhibitors. "
|3.||Acute Kidney Injury (Acute Renal Failure)
|4.||Renal Insufficiency (Renal Failure)
|1.||Peptide Hydrolases (Proteases)
|2.||plasmepsin (plasmepsin I)
|3.||Aspartic Acid Proteases
|5.||Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)
|6.||Cytochrome P-450 Enzyme System (Cytochrome P450)